Parabilis Medicines, formerly known as Fog Pharmaceuticals, is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to developing innovative medicines for individuals affected by severe diseases, with a primary focus on oncology. Parabilis aims to overcome the limitations of existing treatments by targeting traditionally undruggable intracellular protein-protein interactions. The company's mission is to create medicines that can achieve extraordinary outcomes for people affected by severe diseases.
Parabilis's strategic focus centers on its proprietary Helicon™ platform, which integrates advanced AI and experimental technologies to engineer stabilized helical peptide therapeutics. This platform enables the targeting of intracellular protein-protein interactions previously considered intractable. The company's core objectives include developing functional inhibitors, targeted protein degraders, and radiopharmaceuticals to address unmet needs in oncology. Parabilis primarily targets conditions such as colorectal cancer and prostate cancer, aiming to provide novel therapeutic options for these challenging diseases.
In early 2024, Parabilis Medicines secured a $145 million Series E financing round to support the ongoing clinical development of its lead program, FOG-001, and to accelerate its broader Helicon peptide portfolio and platform. To date, the company has raised over $500 million from leading life sciences investors, ensuring robust financial backing for its research and development initiatives.
Parabilis's lead candidate, FOG-001, is a first-in-class direct inhibitor of the β-catenin:TCF interaction, a known driver in colorectal cancer and other solid tumors. FOG-001 is currently undergoing a Phase 1/2 clinical trial (NCT05919264) to evaluate its safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity in patients with microsatellite stable colorectal cancer (MSS CRC) and other solid tumors with Wnt pathway activating mutations. Early clinical data have demonstrated monotherapy antitumor activity and in-tumor target engagement. Preliminary Phase 1/2 data are expected to be shared publicly in 2025.
Parabilis's Helicon™ platform is a seamless integration of AI and experimental technologies designed to discover, optimize, and deliver stabilized helical peptide therapeutics. The platform leverages a vast library of non-canonical amino acids and proprietary linkers to stabilize peptides into an alpha-helical conformation, enabling the targeting of intracellular protein-protein interactions. Advanced AI and physics-based computational methods inform Helicon design and optimization, while custom experimental systems generate extensive datasets to refine these models. This innovative approach allows Parabilis to address previously undruggable targets and develop therapies with enhanced precision and efficacy.
Parabilis Medicines is led by a team of experienced professionals with diverse backgrounds in clinical development, data science, biology, peptide chemistry, and business execution. Key members include:
- Mathai Mammen, M.D., Ph.D.: CEO, President, and Chairman.
- Brandon Allgood, Ph.D.: Chief Data Science Officer.
- Markus Haeberlein, Ph.D.: Executive Vice President, Discovery Science.
- Jonathan Hurov, Ph.D.: Executive Vice President, Discovery Biology.
- Teresa Jurgensen, J.D.: Executive Vice President, General Counsel.
- Thomas Kotarakos: Executive Vice President, Finance.
- John McGee, Ph.D.: Scientific Co-Founder and Senior Vice President, Platform Technology.
- Rohin Mhatre, Ph.D.: Chief Technical Operations Officer.
- Greg Miller: Chief Business Officer.
- Richa Poddar: Senior Vice President, Commercial Strategy & Medical Affairs.
- Kristen Stants: Chief People Officer.
This leadership team brings a wealth of expertise to drive Parabilis's mission forward.
In November 2024, Parabilis Medicines announced a strategic research and data science partnership with nference to support the clinical development of FOG-001 in colorectal cancer. This collaboration provides Parabilis with access to a vast repository of longitudinal, multimodal clinical data from millions of cancer patients, enhancing target identification and clinical biomarker discovery.
Parabilis Medicines operates in the highly competitive oncology therapeutics market, which is characterized by rapid innovation and significant investment. The company's focus on targeting traditionally undruggable intracellular protein-protein interactions positions it uniquely within this landscape. Key competitors include companies developing small molecule inhibitors, monoclonal antibodies, and other peptide-based therapies aimed at similar oncogenic pathways. Parabilis's proprietary Helicon™ platform and its integration of AI and experimental technologies provide a distinct competitive advantage by enabling the development of therapies that can effectively target previously intractable disease mechanisms.
Parabilis Medicines is strategically positioned to advance its pipeline of first-in-class programs across functional inhibitors, targeted protein degraders, and radiopharmaceuticals. The company's robust financial backing, innovative Helicon™ platform, and experienced leadership team provide a strong foundation for future growth. Upcoming milestones include the public sharing of preliminary Phase 1/2 data for FOG-001 in 2025 and the advancement of additional pipeline programs, such as the ERG degrader for prostate cancer, toward clinical trials. Parabilis's commitment to addressing unmet needs in oncology through innovative therapeutic approaches positions it as a key player in the biopharmaceutical industry.
For more information, please visit Parabilis Medicines' official website:
Social Media Profiles:
